Amneal Pharmaceuticals AMRX reported second-quarter earnings of 9 cents per share, which missed the analyst consensus estimate of 14 cents by 35.71%. This is a 62.5% decrease over earnings of 24 cents per share from the same period last year.
The company reported quarterly sales of $404.642 million, which missed the analyst consensus estimate of $428.58 million by 5.59%. This is a 2.21% decrease over sales of $413.787 million the same period last year.
Amneal Pharmaceuticals lowered its fiscal year 2019 EPS guidance from 94 cents-$1.04 to 52 cents-62 cents versus a 61 cent estimate.
Amneal Pharmaceuticals closed Friday at $3.25. The stock has a 52-week high of $24.48 and a 52-week low of $3.18.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
